American drug-maker Pfizer says its experimental vaccine appears to be more than 90 percent effective in preventing COVID-19. The information came Monday from early results of a Phase 3 study involving about 44,000 volunteers in the United States and other countries. An independent group of scientists also examined the study. Pfizer and its German partner BioNTech are the first drug-makers to show successful data from a large Phase 3 trial of a coronavirus vaccine. The companies also said they have found no serious safety concerns in the testing so far. And they expect to seek emergency use permission from the U.S. Food and Drug Administration (FDA) later this month.
